Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA.
Sibley Heart Center, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA.
J Pediatr. 2021 Feb;229:78-85.e2. doi: 10.1016/j.jpeds.2020.09.044. Epub 2020 Sep 22.
To describe the assessment of Fontan-associated liver disease and determine the clinical and imaging measures that may identify hepatic morbidity risk in isolated heart transplantation candidates and trend those measures post-isolated heart transplantation.
Retrospective analysis of pre-isolated heart transplantation and post-isolated heart transplantation Fontan-associated liver disease (FALD) status using blood tests, magnetic resonance imaging (MRI), and liver biopsy analysis within 6 months before isolated heart transplantation and 12 months after isolated heart transplantation in 9 consecutive patients with Fontan. Pre- and post-isolated heart transplantation standard laboratory values; varices, ascites, splenomegaly, thrombocytopenia (VAST) score; Fontan liver MRI score; liver biopsy scores; Model for End-stage Liver Disease (MELD); MELD excluding the International Normalized Ratio (MELD-XI); AST to platelet ratio index, and cardiac catheterization data were compared.
Pretransplantation maximum MELD and MELD-XI was 15 and 16, respectively. Central venous pressures and VAST scores decreased significantly post-transplantation. In 5 paired studies, Fontan liver MRI score maximum was 10 pretransplantation and decreased significantly post-transplantation. Arterially enhancing nodules on MRI persisted in 2 patients post-transplantation. Pretransplantation and post-transplantation liver biopsy scores did not differ in 4 paired biopsy specimens.
Patients with FALD and MELD <15, MELD-XI <16, Fontan liver MRI score <10, and VAST score ≤2 can have successful short-term isolated heart transplantation outcomes. Liver MRI and VAST scores improved post-transplantation. Post-transplantation liver biopsy scores did not change significantly. Pretransplantation liver biopsy demonstrating fibrosis alone should not exclude consideration of isolated heart transplantation. The persistence of hepatic vascular remodeling and fibrosis post-isolated heart transplantation suggests that continued surveillance for hepatic complications post-transplantation for patients with Fontan is reasonable.
描述法乐四联症相关肝疾病的评估,并确定可能识别孤立性心脏移植候选者肝发病率风险的临床和影像学指标,并对孤立性心脏移植后这些指标进行趋势分析。
对 9 例法乐四联症患者在孤立性心脏移植前 6 个月和孤立性心脏移植后 12 个月内使用血液检查、磁共振成像(MRI)和肝活检分析,对孤立性心脏移植前和孤立性心脏移植后的法乐四联症相关肝疾病(FALD)状态进行回顾性分析。比较了孤立性心脏移植前后的标准实验室值、门脉高压、腹水、脾肿大、血小板减少(VAST)评分、法乐四联症肝脏 MRI 评分、肝活检评分、终末期肝病模型(MELD)、不包括国际标准化比值的 MELD(MELD-XI)、AST 与血小板比值指数以及心导管数据。
移植前最大 MELD 和 MELD-XI 分别为 15 和 16。移植后中心静脉压和 VAST 评分显著降低。在 5 项配对研究中,法乐四联症肝脏 MRI 评分最大值为移植前 10 分,显著降低。MRI 上动脉增强结节在移植后仍存在于 2 例患者中。在 4 对活检标本中,移植前和移植后肝活检评分无差异。
MELD <15、MELD-XI <16、法乐四联症肝脏 MRI 评分 <10、VAST 评分 ≤2 的 FALD 患者可获得成功的短期孤立性心脏移植结果。移植后肝脏 MRI 和 VAST 评分改善。移植后肝活检评分无显著变化。移植前肝活检仅显示纤维化者不应排除孤立性心脏移植的考虑。孤立性心脏移植后肝血管重塑和纤维化的持续存在表明,对法乐四联症患者进行移植后肝并发症的持续监测是合理的。